Enhancing synaptic integrity

We’re discovering and developing first-in-class therapeutics for neurologic diseases driven by synaptic dysfunction

As of November 25, 2019, Rodin Therapeutics has been acquired by Alkermes. This page will be redirected to Alkermes.com in February 2020.

As of November 25, 2019, Rodin Therapeutics has been acquired by Alkermes. This page will be redirected to Alkermes.com in February 2020.